SK Bioscience on Thursday unveiled the new "SKBS 3.0" growth strategy, prioritizing the expansion of cell and gene therapy (CGT) and boosting sales of existing vaccines.

In a public filing, the company unveiled its funding plan to invest about 2.4 trillion won ($1.7 billion) over the next five years until 2027.

The company plans to use the capital in four areas -- glocalization, Skybox (in-house vaccine project), contract development and manufacturing organization (CDMO), and premium vaccines.